Download presentation
Presentation is loading. Please wait.
1
Antimuscarinic Agents
Atropine 654-2 Anisodamine Scopolamine Smooth muscle relax weak similar Glands secrete potent Eye mydriasis Cardiovascular tachycardia CNS excite Sedation hypnosis LD50mg/kg 98 115 155
2
Antimuscarinic agents
Atropine 654-2 Anisodamine Scopolamine application Gastrointestinal spasm Ophthalmologic disorders Arrhythmia Infectious shock Organophosphates poisoning Preanesthetic treatment Motion sickness Parkinsonism
3
Categories of Autonomic Pharm
Sympathetic Adrenergic Parasympathetic Cholinergic Adrenaline Rush Agonist Antagonist
4
Chapter 10: Adrenoceptor- Activating Drugs
Autonomic Drugs Chapter 10: Adrenoceptor- Activating Drugs “Fight & Flight”
5
Adrenoceptor-Activating Drugs
Drugs that activate adrenoceptors and exert their effects mimic adrenaline, which will increase the sympathetic nervous system response
6
Adrenoceptor-Activating Drugs
Similar Terminologies: - Adrenoceptor Stimulants - Adrenergic Agonists - Sympathomimetics (mimic, imitate) - Adrenergics / Adrenomimetics - Adrenaline Receptor Agonists/Stimulants
7
Adrenoceptor-Activating Drugs
Classification By mechanism of action - direct: bind directly to receptor - indirect: inhibit CA transporter inhibit storage of NE - mixed: both direct and indirect NE
8
Indirect-acting agonists
9
Adrenoceptor-Activating Drugs
Classification By their spectrum of action depending on the type of primary receptors - alpha (α) - beta (β) - both (α、 β)
10
Adrenoceptor-Activating Drugs
① Ad or Ep ② Dopamine, DA ③ Ephedrine α, β-receptors activating drugs α-receptors activating drugs β-receptors activating drugs NA or NE Metaraminal (Aramine) Phenylephrine(neosnephrine) Methoxamine ① β-R agonist: isoprenaline ② β1-selective agonist: dobutamine ③ β2-selective agonist: salbutamol
11
Adrenoceptor-Activating Drugs
Adrenoceptors (potency of Ad, NE, and other adrenoceptor agonists) α- adrenoceptor α1 (α1A, α1B, α1D) , α2 β- adrenoceptor β1, β2, β3 Dopamine Receptor only activated by dopamine
12
Adrenoceptor-Activating Drugs
13
Adrenoceptor-Activating Drugs
Direct-Acting Adrenoceptor Agonists Catecholamines - Dopamine (DA) - NE (NA) Natural - AD (EP) Isoprenaline Noncatecholamines - Ephedrine - Conidine - Midodrine - Phenylephrine Synthetic
14
Adrenoceptor-Activating Drugs
Basic structure of catecholamine
15
Adrenoceptor-Activating Drugs
Basic structure of catecholamine a. the benzene ring – Catechol moiety b. the amino group c. the α-carbon Ethylamine d. the β-carbon
16
Adrenoceptor-Activating Drugs
Structure-Activity relationship β α
17
Adrenoceptor-Activating Drugs
General Properties of Catecholamine Rapidly inactivated - gut, liver (MAO & COMT) Low oral bioavailabilities Short plasma half life Ad. parenterally
18
Adrenoceptor-Activating Drugs
α- Adrenoceptors α1-R: S.M: contraction - vascular S.M - iris dilator muscle - lower urinary S.M (sphincter of bladder, urethra, & prostate) Exocrine glands: secretion CNS: excitation M-R Iris dilator muscle α1-R
19
Adrenoceptor-Activating Drugs
α- Adrenoceptors α2-R: Presynaptic neurons: autoreceptor, NE Tissues - ocular: aqueous humor - adipose: inhibition of lipolysis - intestinal: secretion - endocrine tissue: insulin Blood platelets: aggregation
20
Adrenoceptor-Activating Drugs
NA (NE) Chemistry: unstable Pharmacokinetics: - intravenous infusion - not across BBB - short duration of action, metabolized by MAO and COMT - excretion by urine
21
Adrenoceptor-Activating Drugs
NA (NE) Postganglionic 10%-20% of catecholamine Direct-acting Activate α(α1 &α2 ) -R strongly and β1 weakly
22
Adrenoceptor-Activating Drugs
NE (NA) Cardiovascular Effects Vascular S.M contraction Total Peripheral Resistance Stroke Volume Coronary Flow Skin, renal, intestinal, hepatic blood flow SBP DBP Compensatory vagal reflex HR or Unchanged
23
Adrenoceptor-Activating Drugs
NE (NA) Other Effects Not prominent in human Large dose: metabolic effects similar to those produced by Ad
24
Adrenoceptor-Activating Drugs
Clinical Uses of NE Early phase of neurogenic shock eg. extreme pain, being shocked blood vessels dilated hypotension b. Hypotension caused by drug toxication (α-R blockers) c. Upper digestive tract bleeding, orally
25
Adrenoceptor-Activating Drugs
Adverse Effects of NE Local tissue marked ischemia and necrosis, procaine or phentolamine can be used to relieve them Acute renal dysfunction
26
Adrenoceptor-Activating Drugs
Contraindications of NE Hypertension, atherosclerosis, coronary heart disease, oliguria, and anuria
27
Adrenoceptor-Activating Drugs
Metaraminol or Aramine Chemistry: stable Direct and Indirect acting Long duration of action, metabolized by MAO and COMT
28
Adrenoceptor-Activating Drugs
Metaraminol or Aramine Both iv. infusion and im. Produce tachyphylaxis Less side effects than NA Used to treat hypotensive states as a substitute for NA
29
Adrenoceptor-Activating Drugs
Isoprenaline: synthetic β(β1, β2 , β3 – adrenoceptor agonist Chemistry: unstable Inhalation as aerosol or sublingual Absorbed fast Not across BBB
30
Adrenoceptor-Activating Drugs
β- Adrenoceptors β1-R: Positive chronotropic effect Positive inotropic effect Positive dromotropic effect Renin secretion from renal juxtaglomerular cells
31
Adrenoceptor-Activating Drugs
β- Adrenoceptors β2-R: S.M: relax - bronchial, uterine, vascular S.M of skeleton: mediate potassium uptake Liver: mediate glycogenolysis BG Renin secretion from renal juxtaglomerular cells
32
Adrenoceptor-Activating Drugs
β- Adrenoceptors β3-R: produce lipolysis: release of fatty acids
33
Adrenoceptor-Activating Drugs
Isoprenaline: synthetic Duration of action longer than Ep Most are destroyed by COMT, few by MAO Excretion by urine Pharmacodynamics: extremely potent β-R(β1, β2) agonist, having little effect on α-R
34
Adrenoceptor-Activating Drugs
Isoprenaline: synthetic Cardiac Effects β1-R Chronotropic Effects (HR ) Cardiac output Cardiac Stimulation Dromotropic Effects (cardiac impulse conduction velocity ) Inotropic Effects (contractility ) Oxygen Consumption
35
Adrenoceptor-Activating Drugs
Isoprenaline: synthetic Blood Vessels: ① A potent vasodilator β2-R Total Peripheral Resistance DBP ② The blood flow of coronary artery
36
Adrenoceptor-Activating Drugs
Isoprenaline: synthetic Smooth Muscles: ① Bronchial SM: Relaxation β2-R Bronchodilation ② GI S: Relaxation
37
Adrenoceptor-Activating Drugs
Isoprenaline: synthetic Inhibit antigen induced release of histamine Metabolism increases Blood Glucose
38
Adrenoceptor-Activating Drugs
Isoprenaline: synthetic Clinical uses Bronchial asthma: control acute attack, sublingual or inhalation c. Serious atria-ventricular conduction blocking: sublingual or intravenous infusion
39
Adrenoceptor-Activating Drugs
Isoprenaline: synthetic Clinical uses Cardiac arrest: intraventricular injection Infectious shock: - central venous pressure - cardiac output - peripheral resistance
40
Adrenoceptor-Activating Drugs
Isoprenaline: synthetic Side effects: palpitation, sinus tachycardia, provoke serious arrhythmias, flushing
41
Adrenoceptor-Activating Drugs
Isoprenaline: synthetic Contraindication: coronary artery disease, hyperthyroid
42
Adrenoceptor-Activating Drugs
Dobutamine: synthetic Selective β1-agonist No effect by orally administration, should be given intravenously Positive inotropic action stronger than chronotropic action Treatment for acute cardiogenic shock or heart failure
43
Adrenoceptor-Activating Drugs
Dobutamine: synthetic Adverse effects: blood pressure , palpitation, headache, ventricular arrhythemia Contraindication: myocardial disease with hypertrophy, atria fibrillation,
44
Adrenoceptor-Activating Drugs
α,β-adrenoceptor agonists Adrenaline or Epinepherine Dopamine, DA Ephedrine
45
Adrenoceptor-Activating Drugs
Adrenaline or Epinepherine (Ad or Ep) Chemistry: unstable Pharmacokinetics: - iv, im or sc. infusion - not across BBB - short duration of action, metabolized by MAO and COMT - excretion by urine
46
Adrenoceptor-Activating Drugs
Ad (Ep) Adrenal Medulla Direct-acting Activate both α(α1, α2 and β(β1, β2 ) receptors strongly
47
Adrenoceptor-Activating Drugs
Ad (Ep) Cardiac Effects (β1, β2 -R) Marked positive chronotropic effect on both normal and abnormal pacemaker activity Strong positive inotropic effect on intrinsic contractility
48
Adrenoceptor-Activating Drugs
Ad (Ep) Cardiac Effects (β1, β2 -R) Promote conduction of heart Cardiac output Oxygen consumption Relax coronary arteries
49
Adrenoceptor-Activating Drugs
Ad (Ep) Vascular Effects (α1, β1, β2 -R) Chief action: smaller arterioles and precapillary sphincters Low dose: activate β2-R on the smooth muscles relaxation Large dose: strongly activate α1-R on the smooth muscles peripheral vascular resistance
50
Adrenoceptor-Activating Drugs
Ad (Ep) Vascular Effects (α1 ,β1, β2 -R) d. Blood pressure low dose: SBP increased, DBP normal or decreased (heart β1-R and peripheral β2-R) large dose: markedly increase BP (peripheral α1-R and β1-R of juxtaglomerular cells, excretion renin)
51
Adrenoceptor-Activating Drugs
Ad (Ep) Other Effects Smooth muscles bronchial SM: relaxation, β2-R (+), strong GI tract tone decreased, β1-R (+)
52
Adrenoceptor-Activating Drugs
Ad (Ep) Other Effects Metabolism ① lipolysis , β3-R (+) ② glycogenolysis in liver , BG markedly, αand β2-R (+), ③ plasma potassium ion when stress or exercise, β2-R (+)
53
Adrenoceptor-Activating Drugs
Ad (Ep) Other Effects counteract the effects of histamine and other mediators released from mast cells and basophils during immediate hypersensitivity reactions
54
Adrenoceptor-Activating Drugs
Clinical Uses of EP Cardiac arrest Anaphylactic shock: sc or im Bronchial asthma: sc or im Local application: local anesthesia (1:250000), stop bleeding
55
Adrenoceptor-Activating Drugs
Adverse Effects of EP BP marked elevation, cerebral hemorrhage or pulmonary edema Severe angina or myocardial infarction Sinus tachycardia or serious ventricular arrhythmias
56
Adrenoceptor-Activating Drugs
Contraindications of EP hypertension, sclerosis of cerebral artery, ischemic heart disease, congestive heart failure, hyperthyroidism, and diabetes, use with care for old patients.
57
Adrenoceptor-Activating Drugs
Dopamine (DA) Pharmacokinetics precursor of NA and Ad intravenous infusion, destroyed by MAO & COMT rapidly t1/2=1-2 min can’t across BBB
58
Adrenoceptor-Activating Drugs
DA: Pharmacodynamics Low concentration: activates DA1-R in renal, coronary artery and mesentery vascular beds vasodilation Large dose: activate β1-R and α-R vasoconstriction, including renal blood vessels, BP
59
Adrenoceptor-Activating Drugs
DA: Pharmacodynamics Release of NA from nerve endings Infusion of low dose: glomerulus filtration rate, renal blood flow and sodium ions excretion
60
Adrenoceptor-Activating Drugs
DA: Clinical Uses: Treatment of various shock Acute renal dysfunction and heart failure, combination of dopamine and diuretics
61
Adrenoceptor-Activating Drugs
DA: Adverse Effects: If infused very fast, it may induce tachycardia, arrhythmia, headache and hypertension
62
Adrenoceptor-Activating Drugs
Ephedrine: plant alkaloid Activate both αand β-Rs Direct acting Indirect acting: enhances the release of NA from adrenergic nerve endings
63
Adrenoceptor-Activating Drugs
Ephedrine: plant alkaloid Stable chemistry property, has effect after oral administration Sympathomimetic action less than ad. But longer duration than that of ad Marked excitement effects of CNS, because it can across BBB Produce tachyphylaxis rapidly
64
Adrenoceptor-Activating Drugs
Ephedrine: Clinical Uses: Bronchial asthma, light symptoms Nasal decongestant Prevent hypotension induced by peidermal anesthesia or subarachnoid anesthesia Relieve symptoms of allergic reaction on the skin and mucous membrane
65
Adrenoceptor-Activating Drugs
Ephedrine Adverse Effects: anxiety, insomnia, tachyphylaxis
66
Adrenoceptor-Activating Drugs
Ephedrine Contraindication: hypertension, atherosclerosis, hyperthyroidism, and coronary heart disease
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.